Figures
Abstract
The molecular mechanisms underlying cerebral angiogenesis have not been fully investigated. Using primary mouse brain endothelial cells (MBECs) and a capillary-like tube formation assay, we investigated whether the sonic hedgehog (Shh) signaling pathway is coupled with the plasminogen/plasmin system in mediating cerebral angiogenesis. We found that incubation of MBECs with recombinant human Shh (rhShh) substantially increased the tube formation in naïve MBECs. This was associated with increases in tissue plasminogen activator (tPA) activation and reduction of plasminogen activator inhibitor 1 (PAI-1). Blockage of the Shh pathway with cyclopamine abolished the induction of tube formation and the effect of rhShh on tPA and PAI-1. Addition of PAI-1 reduced rhShh-augmented tube formation. Genetic ablation of tPA in MBECs impaired tube formation and downregulated of vascular endothelial growth factor (VEGF) and angiopoietin 1 (Ang1). Addition of rhShh to tPA−/− MBECs only partially restored the tube formation and upregulated Ang1, but not VEGF, although rhShh increased VEGF and Ang1 expression on wild-type MBECs. Complete restoration of tube formation in tPA−/− MBECs was observed only when both exogenous Shh and tPA were added. The present study provides evidence that tPA and PAI-1 contribute to Shh-induced in vitro cerebral angiogenesis.
Citation: Teng H, Chopp M, Hozeska-Solgot A, Shen L, Lu M, Tang C, et al. (2012) Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1 Contribute to Sonic Hedgehog-Induced In Vitro Cerebral Angiogenesis. PLoS ONE 7(3): e33444. https://doi.org/10.1371/journal.pone.0033444
Editor: Cesario V. Borlongan, University of South Florida, United States of America
Received: November 25, 2011; Accepted: February 9, 2012; Published: March 14, 2012
Copyright: © 2012 Teng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the U.S. National Institutes of Health (PO1 NS23393 to MC, RO1 AG037506 to MC, and RO1 NS075156 to ZGZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Stroke induces angiogenesis during the process of brain repair, and angiogenesis in the ischemic brain is related to improvement of functional outcome [1], [2], [3], [4]. Angiogenesis consists of a series of endothelial cellular events, including proliferation, migration, formation of tube like structures, and maturation into new blood vessels [5], [6]. Molecular mechanisms underlying cerebral angiogenesis have not been extensively investigated.
Sonic hedgehog (Shh), a member of the family of the hedgehog proteins [7], mediates angiogenesis during development [8], [9] and under pathological conditions [10], [11], [12]. Shh binds to its transmembrane receptor Patched (Ptch) [12] that results in the activation of the transmembrane protein smoothened (Smo), and subsequently triggers an intracellular signal transduction pathway that leads to the activation of the Gli transcription factors [7]. Shh has been implicated in the induction of cerebral angiogenesis [13], [14]. Shh mediates neural tube angiogenesis during embryonic development [14]. In vitro, Shh induces capillary tube formation in a murine brain capillary endothelial cell line [13].
Plasminogen activators, tPA and urokinase plasminogen activator (uPA), convert plasminogen into plasmin [15]. Plasmin regulates angiogenesis directly by degrading matrix molecules and indirectly by activating extracellular matrix metalloproteinases and angiogenic growth factors [16], [17]. Plasminogen activator inhibitor 1 (PAI-1) also plays a critical angiogenic role [18], [19], [20]. In the cerebral circulation, cerebral endothelial cells are primary contributors of tPA and PAI-1 [21].
We and others have recently demonstrated that astrocytes secrete Shh and cerebral endothelial cells express Ptch, Smo, and Gli1 [22], [23]. Thus, the possibility arises that activation of the Shh signaling pathway in cerebral endothelial cells by secreted Shh interacts with tPA and/or PAI to induce angiogenesis. Accordingly, we hypothesized that the interaction between the Shh signaling pathway and the plasminogen and plasmin system mediates cerebral angiogenesis. In the present study, using primary mouse brain endothelial cells (MBECs) and a capillary-like tube formation assay, we tested this hypothesis. Our data show that tPA and PAI-1 are required for Shh-induced cerebral angiogenesis, thereby suggesting that their crosstalk plays an important in cerebral angiogenesis.
Results
The Shh pathway promotes capillary-like tube formation in cerebral endothelial cell
Using a capillary tube formation assay, we examined the effect of Shh on in vitro angiogenesis. Incubation of primary MBECs with rhShh (100 ng/ml) in Matrigel for 16 h significantly increased the number of tubes compared with the number in the control group (Fig. 1A, B, and D). We then examined whether rhShh affects its receptor and Gli1 expression on the MBECs. Quantitative real-time RT-PCR analysis revealed that treatment of MBECs with rhShh upregulated mRNA levels of Ptch, a Shh receptor, and Gli1, a transcription factor (Fig. 1E, F, and Figure S1 A to D). Blockage of the Shh pathway with a specific inhibitor of the Smo, cyclopamine (5 µM), abolished the rhShh-increased tube formation (Fig. 1C, D). These data indicate that exogenous Shh promotes angiogenesis in naive cerebral endothelial cells.
Panels A to C show representative images of capillary-like tube formation of primary cerebral endothelial cells incubated with control medium (A), rhShh (B), and rhShh in presence of cyclopamine (C). Panel D shows quantitative data of capillary-like tube lengths in mm/mm2 (n = 6/group). Real-time RT-PCR analysis (n = 3/group) showed that rhShh substantially increased mRNA levels of Ptch (E), a Shh receptor, and Gli 1(F), a transcription factor in endothelial cells. *p<0.05 the control group, # p<0.05 versus the rhShh group. Bar = 100 µm. WT = wild-type. CY = cyclopamine.
tPA and PAI-1contribute to Shh-enhanced capillary tube formation
To examine the effect of rhShh on the plasminogen/plasmin system, we measured mRNA and protein levels of genes in this system. Quantitative real-time RT-PCR analysis of naïve MBECs revealed that rhShh significantly upregulated tPA (Fig. 2A), but not uPA expression (Fig. 2B) and downregulated PAI-1 expression (Fig. 2C) compared with the endothelial cells in the control group. In parallel, zymography and Western blot analyses showed that rhShh significantly increased tPA activity (Fig. 2D, E) and protein levels (Fig. 2F, G), and substantially decreased PAI-1 protein levels (Fig. 2H, I). Blockage of Smo with cyclopamine suppressed rhShh-upregulated tPA expression (2.3±0.2 vs 8.3±1.1 in rhShh, n = 3/group, p<0.05) and restored PAI-1 expression (1.3±0.1 vs 0.2±0.07 in rhShh, n = 3/group, p<0.05). These data indicate that the Shh signaling pathway affects the plasminogen/plasmin system by activation of tPA and downregulation of PAI-1 expression on MBECs.
Real-time RT-PCR analysis (n = 3/group) revealed that incubation of endothelia cells with rhShh significantly increased tPA mRNA levels (A) and reduced PAI-1 mRNA (C), but did not alter uPA mRNA levels (B). Zymography and Western blot analysis (n = 3/group) showed that rhShh significantly increased PA activity (D and E), protein expression (F and G), and reduced PAI-1 proteins (H and I), respectively. *p<0.05 compared to the control group. WT = wild-type.
We next examined whether activation of tPA by rhShh is required for rhShh-induced capillary tube formation by employing primary cerebral endothelial cells harvested from tPA−/− mice. Quantitative real-time RT-PCR analysis of the tPA−/− cerebral endothelial cells showed that tPA mRNA levels were almost undetectable (0.07±0.01, n = 3), while uPA levels were not altered (1.1±0.2, n = 3) compared to levels on wild-type endothelial cells (1.0±0.1, n = 3). The capillary tube formation assay showed that the tPA−/− endothelial cells exhibited an 87% reduction of capillary-like tube formation (Fig. 3C, G) compared to wild-type endothelial cells (Fig. 3A, G). To examine whether exogenous tPA can restore capillary tube formation of the tPA−/− endothelial cells, rhtPA was added. Surprisingly, exogenous rhtPA only modestly restored capillary tube formation of the tPA−/− endothelial cells in a dose-dependent manner (Fig. 3E, G, and H). Addition of rhShh into the tPA−/− endothelial cells also modestly increased the tube formation (Fig. 3D, G) compared with the tPA−/− endothelial cells (Fig. 3C, G). However, incubation of the tPA−/− endothelial cells with both rhtPA and rhShh fully restored the tube formation, which significantly surpassed tube formation levels of wild-type endothelial cells (Fig. 3F, G). These data suggest that tPA and Shh contribute to in vitro cerebral angiogenesis.
Panels A to F show representative images of capillary-like tube formation of primary cerebral endothelial cells incubated with control medium (A), rhShh (B), tPA−/−cerebral endothelial cells (C), tPA−/−cerebral endothelial cells incubated with rhShh (D), tPA−/−cerebral endothelial cells incubated with htPA (E), and), tPA−/−cerebral endothelial cells incubated with rhShh and htPA (F). Panel G shows quantitative data of capillary-like tube lengths in mm/mm2 among different experimental groups (n = 6/group). Panel H shows the effect of different doses of exogenous tPA on capillary-like tube formation on tPA−/− cerebral endothelial cell (n = 6/group). *p<0.05 versus the tPA−/−group, # p<0.05 versus the tPA−/−+tPA group, ∧p<0.05 versus the tPA−/−+Shh group, $ p<0.05 vs the tPA−/−+tPA+Shh group, & p<0.05 versus the WT group, and + p<0.05 versus the tPA−/−+tPA+Shh group. Bar = 100 µm. WT = wild-type. tPA−/− = tPA knockout.
To examine whether PAI-1 contributes to Shh-induced tube formation, we incubated wild-type endothelial cells with PAI-1 (10 µg/ml) in the presence of rhShh and found that exogenous PAI-1 significantly reduced rhShh-increased tube formation (Fig. 4C, D and E), although exogenous PAI-1 alone did not affect baseline tube formation (Fig. 4A, B, and E). Furthermore, addition of PAI-1 into tPA−/− endothelial cells treated with rhtPA and rhShh partially, but significantly reduced tube formation (Fig. 3G). These suggest that PAI-1 is also involved in Shh-induced angiogenesis.
Panels A to D show representative images of capillary-like tube formation of primary cerebral endothelial cells incubated with control medium (A), PAI-1(B), rhShh (C), and rhShh with PAI-1(D). Panel E shows quantitative data of capillary-like tube lengths in mm/mm2 among different experimental groups (n = 5/group).* p<0.05 the control group. # p<0.05 versus the rhShh group. Bar = 100 µm.
Upregulation of Ang1 and VEGF by Shh is tPA dependent and independent, respectively
Previous studies have shown that Shh upregulates VEGF and Ang1 in fibroblasts and interstitial mesenchymal cells [10], [11]. We therefore examined the effect of rhShh on expression of these genes in cerebral endothelial cells. Both real-time RT-PCR analysis and Western blot showed that rhShh significantly upregulated Ang1 and VEGF expression on wild-type endothelial cells (Fig. 5A to F). Blockage of Tie2 with a neutralizing antibody against Tie2 significantly reduced rhShh-induced tube formation (3.9±1.1 vs 6.4±0.4 mm/mm2 in rhShh group, n = 5/group, p<0.05), while inhibition of VEGF receptor 2 (VEGFR2) with SU1498, a specific antagonist of VEGFR2, did not significantly reduce rhShh-induced tube formation (4.1±1.2 vs 6.4±0.4 mm/mm2 in rhShh group, n = 5, p = 0.09). Interestingly, tPA−/− endothelial cells exhibited significant reductions of Ang1 mRNA and protein (Fig. 5A, C, D), and a significant decrease in VEGF protein (Fig. 5B, E, F) compared to wild-type endothelial cells, suggesting that knockout of tPA affects Ang 1 and VEGF expression. Incubation of tPA−/− endothelial cells with rhShh robustly upregulated Ang 1, but did not alter VEGF expression (Fig. 5A to F). These data suggest that Shh-upregulated Ang1 is tPA independent, whereas upregulation of VEGF by Shh requires tPA.
Real-time RT-PCR (A, B) and Western blot (C to F) analyses showed that rhShh robustly increased Ang1 (A, C, D) and VEGF (B, E, F) expression in wild-type (WT) MBECs. Knockout of tPA (tPA−/−) substantially reduced Ang1 expression compared with wild-type MBECs (A, C, D), whereas incubation of tPA−/− MBECs with rhShh completely rescued Ang1 expression (A, C, D). However, incubation of tPA−/− MBECs with rhShh did not elevate VEGF expression, although knockout tPA significantly reduced VEGF protein levels (B, E, F). * p<0.05 versus the WT group, # p<0.05 versus the tPA−/− group. (n = 3/group). MBECs = mouse brain endothelial cells.
Discussion
The present study demonstrates that Shh promotes in vitro cerebral angiogenesis and that tPA and PAI-1 are involved in this process.
A prominent effect of the morphogen Shh on angiogenesis is emerging. Our observations that rhShh upregulated Gli1 and that blockage of Smo by cyclopamine abolished the effect of rhShh on the tube formation indicate that the Shh/Gli1 pathway mediates cerebral angiogenesis. These data are consistent with a previous study on mouse brain capillary endothelial cells, which shows that blockage of cyclopamine suppresses the effect of rhShh on capillary morphogenesis [13]. We noted that the dose of rhShh used in the present study (100 ng/ml) was fifty times lower than the dose in the Kanda et al study (5 µg/ml) [13]. This difference could be caused by use of different recombinant Shh, rhShh vs mouse recombinant Shh in the Kanda et al study [13]. Alternatively, primary cerebral endothelial cells used in the present study are more sensitive to exogenous Shh. A very recent study shows that rhShh at dose of 0.1 µg/ml regulates blood brain barrier (BBB) permeability in primary human brain endothelial cells [22].
Mechanisms by which Shh induces angiogenesis are incompletely understood. The present study indicates a linkage between the Shh signaling pathway and the plasminogen and plasmin system in mediating in vitro cerebral angiogenesis. The effect of exogenous Shh on tPA and PAI-1 is specific because rhShh does not alter uPA expression and blockage of the Shh pathway with cyclopamine abolishes tPA activation and restores PAI-1 expression on cerebral endothelial cells. In addition, both Shh and tPA are required to fully restore in vitro angiogenesis in tPA−/− cerebral endothelial cells. Cerebral endothelial cells are primary sources of tPA and PAI-1 [21]. tPA, a serine protease, converts plasminogen to plasmin, whereas PAI-1 neutralizes plasminogen activator activation that prevents the generation of plasmin [24]. The plasminogen and plasmin system regulates angiogenesis [16], [17]. Thus, activation of the Shh signaling pathway could regulate levels of tPA and PAI-1 on cerebral endothelial cells, which has also been recently demonstrated by us to occur in astrocytes [23], suggesting that interaction of the Shh pathway with the plasminogen/plasmin system is not cell type specific. Kanda et al previously demonstrated that Shh activates the PI3K pathway, thereby inducing angiogenesis [13]. The PI3K/Akt signaling pathway regulates tPA and PAI-1 levels [25]. Additional studies are warranted to investigate whether the PI3K/Akt pathway mediates crosstalk between the Shh pathway and the plasminogen/plasmin system.
Consistent with published data, the present study demonstrates that Shh upregulates proangiogenic factors VEGF and Ang1 on cerebral endothelial cells [13], [14]. Angiogenesis induced by tPA is mediated by elevation of VEGF [26]. Our data demonstrate that ablation of tPA substantially reduced endogenous Ang1 and VEGF expression on cerebral endothelial cells, which could account for observed impairment of tube formation. Our data further indicate that Shh regulates VEGF expression on cerebral endothelial cells in a tPA-dependent manner, as exogenous Shh could not upregulate VEGF expression on tPA−/− endothelial cells. In contrast, endogenous tPA is not required for Shh-induced Ang1 expression, since rhShh elevated Ang1 levels in tPA−/− endothelial cells, as rhShh did on wild-type endothelial cells. Studies in mesenchymal cells suggest that Shh induces Ang1 through activation of the orphan nuclear receptor, COUPTFII [27]. Thus, the present study reveals coupling of Shh and tPA in mediating cerebral angiogenesis by regulating proangiogenic factors. While our manuscript was under review, Alvarez et al showed that the Shh secreted by astrocytes interacts with cerebral endothelial cells to facilitate formation of BBB integrity and to reduce inflammation in vivo [22]. Further studies are needed to investigate whether coupling of the Shh pathway and the plasminogen/plasmin system plays a role in BBB function.
In summary, the present study demonstrates that tPA and PAI-1 are involved in Shh-induced in vitro cerebral angiogenesis, which suggests complex coupling between the Shh signaling pathway and the plasminogen/plasmin system for inducing angiogenesis.
Materials and Methods
All experimental procedures were approved by the institutional Animal Care and Use Committee of Henry Ford Hospital. Wild-type mice (C57BL6/J, 6–8 weeks) and tPA null mice (tPA−/− mice, C57BL6 background) were purchased from the Jackson Laboratory (Bar Harbor, ME). The permit number is: #886.
Culture of mouse brain microvascular endothelial cells
Cerebral endothelial cells were isolated from microvessels of wild-type (n = 10) or tPA knockout mice (n = 10) as previously described [28]. Briefly, mice were sacrificed and their brains were collected in RPMI 1640 medium (Invitrogen Cooperation, Carlsbad, CA) supplemented with 1% penicillin and streptomycin (Invitrogen Corporation, Carlsbad, CA). Cerebellum, white matter, meninges, and visible blood vessels of the brain were removed under a microscope. Cerebral cortex and subcortex were cut into small pieces and homogenized. Homogenates were suspended in 15% dextran (Sigma, St. Louis, MO) and centrifuged at 6,000 g for 15 min at 4°C. Pellets were resuspended and digested with 0.1% collagenase/dispase (Roche Applied Science, Penzberg, Germany) and 2% FBS (Invitrogen) in RPMI1640 medium. Digested microvessels were separated with 45% Percoll (Sigma, St. Louis, MO) at 20,000 g for 10 min at 4°C and plated into collagen I (BD Biosciences, Bedford, MA) coated plates. Cultures were maintained in endothelial growth medium. Passage 2–4 endothelial cells were employed in the present study.
Capillary tube formation assay
Ninety-six well plates were coated with 100 µl solution containing 70% matrigel (BD Biosciences) and 30% DMEM (Invitrogen). MBECs were incubated with or without rhShh (100 ng/ml) (R&D System, Minneapolis, MN), cyclopamine (5 µM) (EMD-Calbiochem, Gibbstown, NJ), rhtPA (1 µM) (EMD-Calbiochem), or PAI-1 (10 ug/ml) (EMD-Calbiochem) for 16 h. MBECs (2×104cells/well) were then seeded in the coated 96-well plates for 3–4 hours at 37°C. Formation of capillary-like networks was recorded under a 10× objective (OlympusIX71, Olympus Optical Co, LTD, Tokyo, Japan) via a color CoolSnap CCD camera (Roper Scientific Photometrics, Tucson, Arizona) and the total length of tube formation was measured by means of the microcomputer imaging device (MCID, Imaging Research, St. Catharines, Canada). Data are presented as the length in mm/mm2.
Real time RT-PCR
Quantitative real-time RT-PCR was performed according to published methods [28], [29]. Briefly, total RNA from MBECs was isolated using Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA) and followed by reverse transcription in accordance with the manufacturer's procedure. Real-time PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) on an ABI 7000 PCR instrument (Applied Biosystems). Three-stage program parameters provided by the manufacturer were employed, as follows: 2 min at 50°C, 10 min at 95°C, and then 40 cycles of 15 s at 95°C and 1 min at 60°C. The specificity of PCR product was verified by performing dissociation reaction plots. Each sample was tested in triplicate and data obtained from three independent experiments were used to quantify relative gene expression by the 2−ΔΔCt method. Using Primer Express software (Applied Biosystems), we designed the following primers used in the present study: β-actin (forward, 5′-CCA TCA TGA AGT GTG ACG TTG-3′; reverse, 5′-CAA TGA TCT TGA TCT TCA TGG TG-3′), tPA (forward, 5′-CTG AGG TCA CAG TCC AAG CA-3′; reverse, 5′- ACA GAT GCT GTG AGG TGC AG-3′), PAI-1 (forward, 5′-GTC TTT CCG ACC AAG AGC AG-3′; reverse, 5′- ATC ACT TGG CCC ATG AAG AG-3′), uPA(forward, 5′- AGT GTG GCC AGA AGG CTC TA-3′; reverse, 5′- GCT GCT CCA CCT CAA ACT TC-3′), Ptch1(forward, 5′-GTG GAA GTT GGT GGA CGA GT-3′; reverse, 5′-TAG CGC CTT CTT CTT TTG GA-3′), Gli1(forward, 5′-TCC ACA CGC CCC CTA GTG-3′; reverse, 5′-TGG CAA CAT TTT CGG TGA TG-3′), angiopoietin 1 (Ang1, forward, 5′-CTC GTC AGA CAT TCA TCA TCC AG-3′, reverse, 5′-CAC CTT CTT TAG TGC AAA GGC T-3′), vascular endothelial growth factor (VEGF, forward, 5′-CAG GCT GCT GTA ACG ATG AA-3′; reverse, 5′-GCA TTC ACA TCT GCT GTG CT-3′).
Western blot analysis
Western blot was performed according to published methods [30]. Briefly, equal amounts of protein (40 µg/lane) for each sample were electrophoresed through a 10% SDS-PAGE gel (Invitrogen) and subsequently electrotransferred to nitrocellulose membranes. Membranes were probed with the following primary antibodies: PAI-1(1∶500, Santa Cruz Biotechnology Inc, Santa Cruz, CA), tPA(1∶500, Santa Cruz), Ang 1 (1∶1,000, Abcam, Cambridge, MA), VEGF (1∶500, Santa Cruz), and β-actin (1∶10,000, Abcam) for 16 hrs at 4°C. For detection, horseradish peroxidase-conjugated secondary antibodies were used (1∶2000) followed by enhanced chemiluminescence development (Pierce, Rockford, IL).
Direct casein zymography of plasminogen activator (PA) activity
Proteins from MBECs were separated by 10% SDS-PAGE and PA activity was assayed by zymography, as described previously [31], [32]. Briefly, 30 µg protein samples were mixed with the sample loading buffer without β-ME, and heating was omitted. The mixture of the lower gel (10% acrylamide) contained casein (1 mg/ml) (Sigma) and plasminogen (13 mg/ml) (American Diagnostica, Greenwich, CT) as substrates for plasmin and PA, respectively. The gel was then washed for 30 min with 2.5% Triton X-100 to remove SDS and further washed for 10 min with 0.1 M Tris buffer, pH 8. New Tris buffer was replaced and the gel was incubated for 4 hrs at 37°C to allow caseinolysis occur. On the darkly stained casein background, PA activity was visualized as light bands resulting from casein degradation. To verify loading variations, duplicate samples were used in PAI-1 Western blot. Actin levels were employed as loading control.
Supporting Information
Figure S1.
Representative real-time RT-PCR raw data of reaction (A, C) and dissociation curve (B, D) of Ptch (A, B) and Gli1 (C, D). WT = wild-type.
https://doi.org/10.1371/journal.pone.0033444.s001
(TIF)
Author Contributions
Conceived and designed the experiments: HT MC ZGZ. Performed the experiments: HT AHS LS CT. Analyzed the data: HT ML CT. Contributed reagents/materials/analysis tools: HT AHS ML. Wrote the paper: HT MC ZGZ.
References
- 1. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, et al. (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106: 829–838.
- 2. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, et al. (2002) Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 22: 379–392.
- 3. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM (1994) Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25: 1794–1798.
- 4. Slevin M, Krupinski J, Slowik A, Kumar P, Szczudlik A, et al. (2000) Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. Stroke 31: 1863–1870.
- 5. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932–936.
- 6. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671–674.
- 7. Varjosalo M, Taipale J (2008) Hedgehog: functions and mechanisms. Genes Dev 22: 2454–2472.
- 8. Dyer MA, Farrington SM, Mohn D, Munday JR, Baron MH (2001) Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Development 128: 1717–1730.
- 9. Byrd N, Becker S, Maye P, Narasimhaiah R, St-Jacques B, et al. (2002) Hedgehog is required for murine yolk sac angiogenesis. Development 129: 361–372.
- 10. Pola R, Ling LE, Silver M, Corbley MJ, Kearney M, et al. (2001) The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 7: 706–711.
- 11. Lee SW, Moskowitz MA, Sims JR (2007) Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts. Int J Mol Med 19: 445–451.
- 12. Asai J, Takenaka H, Kusano KF, Ii M, Luedemann C, et al. (2006) Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling. Circulation 113: 2413–2424.
- 13. Kanda S, Mochizuki Y, Suematsu T, Miyata Y, Nomata K, et al. (2003) Sonic hedgehog induces capillary morphogenesis by endothelial cells through phosphoinositide 3-kinase. J Biol Chem 278: 8244–8249.
- 14. Nagase T, Nagase M, Yoshimura K, Fujita T, Koshima I (2005) Angiogenesis within the developing mouse neural tube is dependent on sonic hedgehog signaling: possible roles of motor neurons. Genes Cells 10: 595–604.
- 15. Castellino FJ, Ploplis VA (2005) Structure and function of the plasminogen/plasmin system. Thromb Haemost 93: 647–654.
- 16. Adibhatla RM, Hatcher JF (2008) Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 7: 243–253.
- 17. Mignatti P, Rifkin DB (1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49: 117–137.
- 18. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, et al. (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152: 777–784.
- 19. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, et al. (2002) The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16: 147–154.
- 20. Labied S, Blacher S, Carmeliet P, Noel A, Frankenne F, et al. (2011) Transient reduction of placental angiogenesis in PAI-1-deficient mice. Physiol Genomics 43: 188–198.
- 21. Kim JA, Tran ND, Wang SJ, Fisher MJ (2003) Astrocyte regulation of human brain capillary endothelial fibrinolysis. Thromb Res 112: 159–165.
- 22. Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, et al. (2011) The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 334: 1727–1731.
- 23. Xin H, Li Y, Shen LH, Liu X, Hozeska-Solgot A, et al. (2011) Multipotent mesenchymal stromal cells increase tPA expression and concomitantly decrease PAI-1 expression in astrocytes through the sonic hedgehog signaling pathway after stroke (in vitro study). J Cereb Blood Flow Metab 31: 2181–2188.
- 24. Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, et al. (2009) Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 14: 1337–1361.
- 25. Li PC, Yang CC, Hsu SP, Chien CT (2012) Repetitive progressive thermal preconditioning hinders thrombosis by reinforcing phosphatidylinositol 3-kinase/Akt-dependent heat-shock protein/endothelial nitric oxide synthase signaling. J Vasc Surg.
- 26. Ohki M, Ohki Y, Ishihara M, Nishida C, Tashiro Y, et al. (2010) Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration. Blood 115: 4302–4312.
- 27. Krishnan V, Pereira FA, Qiu Y, Chen CH, Beachy PA, et al. (1997) Mediation of Sonic hedgehog-induced expression of COUP-TFII by a protein phosphatase. Science 278: 1947–1950.
- 28. Teng H, Zhang ZG, Wang L, Zhang RL, Zhang L, et al. (2008) Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. J Cereb Blood Flow Metab 28: 764–771.
- 29. Liu XS, Zhang ZG, Zhang L, Morris DC, Kapke A, et al. (2006) Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J Cereb Blood Flow Metab 26: 787–796.
- 30. Wang L, Zhang ZG, Zhang RL, Gregg SR, Hozeska-Solgot A, et al. (2006) Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 26: 5996–6003.
- 31. Miskin R, Soreq H (1981) Sensitive autoradiographic quantification of electrophoretically separated proteases. Anal Biochem 118: 252–258.
- 32. Ahn MY, Zhang ZG, Tsang W, Chopp M (1999) Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice. Brain Res 837: 169–176.